Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity.

"Conflicts of interest Jan T. Andersen is a co‐inventor of patents, which are entitled ‘Albumin Variants and uses thereof’ and relate to the data described in this paper, for example, EP3063171B1, US10208102 and US10781245. Alessio Branchini received grants and non‐financial support from Grifols. Mirko Pinotti received grants from Novo Nordisk. Alessio Branchini and Mirko Pinotti received grants and personal fees from Pfizer. Francesco Bernardi, received a research grant from Pfizer. The remaining authors have no competing financial interests to declare."

"This study was financially supported by the Bayer Early Career Investigator Award (Bayer Haemophilia Award Programme) 2018 (Alessio Branchini and Mirko Pinotti). Jeannette Nilsen, Kristin H. Aaen and Jan T. Andersen were supported by the Research Council of Norway (Grant no. 274993; 287927), and Jan T. Andersen by the South‐Eastern Norway Regional Health Authority (Grant no. 2018052; 2019084). T.T.G. was supported by internal funding from Division of Head, Neck and Reconstructive Surgery, Oslo University Hospital. The authors would like to thank Simone Mester for contributing with protein for an in vivo experiment. Jan T. Andersen is a co‐inventor of patents, which are entitled ‘Albumin Variants and uses thereof’ and relate to the data described in this paper, for example, EP3063171B1, US10208102 and US10781245. Alessio Branchini received grants and non‐financial support from Grifols. Mirko Pinotti received grants from Novo Nordisk. Alessio Branchini and Mirko Pinotti received grants and personal fees from Pfizer. Francesco Bernardi, received a research grant from Pfizer. The remaining authors have no competing financial interests to declare."